£79.00

It has never been this cheap. We have no record of a lower price.

£79 today · cheaper than every other day in the last 3 months

Ingramcontent Heilbarer metastasierender Krebs: Untersuchungen zur Chemosensitivität von testikulären Tumorzellen gegenüber Cisplatin

View at Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 55 days · 55 data points (no recent data)

Historical
Generating forecast…
£79.00 £75.05 £76.63 £78.21 £79.79 £81.37 £82.95 23 July 2026 05 August 2026 19 August 2026 01 September 2026 15 September 2026
View at Amazon ↗

Price data last checked 36 day(s) ago - refreshing...

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 55 days • 1 price levels

Days at Price
55 days 0 14 28 41 55 £79 Days at Price

Price Analysis

Most common price: £79 (55 days, 100.0%)

Price range: £79 - £79

Price levels: 1 different prices over 55 days

Description

Metastasierender Krebs ist bei Erwachsenen in der Regel nicht heilbar. Eine Ausnahme stellen testikuläre Keimzelltumoren (TKZT) dar, da über 75 % der Patienten mit fortgeschrittenen metastasierenden TKZT mit einer auf Cisplatin basierenden Chemotherapie geheilt werden können. Ein besseres Verständnis der molekularen Grundlagen der chemotherapeutischen Effizienz bei der Behandlung von Testistumoren könnte helfen, die Sensitivität von anderen metastasierenden Tumoren zu erhöhen. In dieser Arbeit wurde zum ersten Mal gezeigt, dass die Testistumorzellen in der Reparatur von Interstrang-Crosslinks (ICL) defizient sind, wobei die verminderte ICL-Reparatur auf die niedrige Menge der DNA-Reparaturproteine ERCC1-XPF zurückgeführt werden konnte. Die Befunde der vorliegenden Studie zeigen, dass ERCC1-XPF ein wichtiger Faktor ist, der die Resistenz gegenüber Cisplatin beeinflussen kann. Ein gezieltes Targeting von ERCC1-XPF könnte nun eingesetzt werden, um die ICL-Reparatur in Tumoren zu reduzieren und somit die Sensitivität gegenüber Cisplatin und weiteren ICL-induzierenden Agenzien zu erhöhen. Somit könnte die Effizienz einer chemotherapeutischen Behandlung möglicherweise gesteigert werden.

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
19 November 2012
Listed Since
21 November 2012

Barcode

No barcode data available

Similar Products You Might Like

Cisplatin: Pharmacology, Clinical Uses & Adverse Effects (Pharmacology - Research, Safety Testing and Regulation: Cancer Etiology, Diagnosis and Treatments)
78% match

Cisplatin: Pharmacology, Clinical Uses & Adverse Effects (Pharmacology - Research, Safety Testing and Regulation: Cancer Etiology, Diagnosis and Treatments)

£86.54 14 Sep 2026
Management of Castration Resistant Prostate Cancer (Current Clinical Urology)
76% match

Management of Castration Resistant Prostate Cancer (Current Clinical Urology)

Humana

£104.33 29 Aug 2026
Clinically Relevant Resistance in Cancer Chemotherapy: 112 (Cancer Treatment and Research, 112)
76% match

Clinically Relevant Resistance in Cancer Chemotherapy: 112 (Cancer Treatment and Research, 112)

Springer

£77.89 15 Sep 2026
Contemporary Research on Renal Cell Carcinoma: Basic and Clinical Developments
74% match

Contemporary Research on Renal Cell Carcinoma: Basic and Clinical Developments

Springer

£76.42 15 Sep 2026
Chemotherapy and Radiotherapy of Gastrointestinal Tumors: 79 (Recent Results in Cancer Research, 79)
74% match

Chemotherapy and Radiotherapy of Gastrointestinal Tumors: 79 (Recent Results in Cancer Research, 79)

Springer

£78.02 12 Sep 2026
Chemosensitivity Testing in Oncology: 161 (Recent Results in Cancer Research, 161)
74% match

Chemosensitivity Testing in Oncology: 161 (Recent Results in Cancer Research, 161)

Springer

£113.93 07 Aug 2026
Anti-Cancer N-Heterocyclic Carbene Complexes of Gold(III), Gold(I) and Platinum(II): Thiol “Switch-on” Fluorescent Probes, Thioredoxin Reductase ... Reticulum Targeting Agents (Springer Theses)
73% match

Anti-Cancer N-Heterocyclic Carbene Complexes of Gold(III), Gold(I) and Platinum(II): Thiol “Switch-on” Fluorescent Probes, Thioredoxin Reductase ... Reticulum Targeting Agents (Springer Theses)

Springer

£74.98 07 Aug 2026
DNA Repair of Cancer Stem Cells
73% match

DNA Repair of Cancer Stem Cells

Springer

£108.01 04 Aug 2026
Cancer Chemotherapy 1: 7 (Cancer Treatment and Research)
73% match

Cancer Chemotherapy 1: 7 (Cancer Treatment and Research)

Springer

£166.02 07 Aug 2026
Chemotherapy and Immunotherapy in Urologic Oncology: A Guide for the Advanced Practice Provider
73% match

Chemotherapy and Immunotherapy in Urologic Oncology: A Guide for the Advanced Practice Provider

Springer

£89.78 21 Oct 2026
Molecular Targeted Therapy of Lung Cancer
73% match

Molecular Targeted Therapy of Lung Cancer

Springer

£113.79 08 Aug 2026
DNA Repair in Cancer Therapy (Cancer Drug Discovery and Development)
73% match

DNA Repair in Cancer Therapy (Cancer Drug Discovery and Development)

Humana

£107.98 07 Aug 2026
Advanced and Metastatic Renal Cell Carcinoma, An Issue of Urologic Clinics (Volume 47-3) (The Clinics: Surgery, Volume 47-3)
73% match

Advanced and Metastatic Renal Cell Carcinoma, An Issue of Urologic Clinics (Volume 47-3) (The Clinics: Surgery, Volume 47-3)

Elsevier

£69.11 13 Sep 2026
Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2
73% match

Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2

Springer

£145.87 07 Aug 2026
Anticancer Drug Resistance: Advances in Molecular and Clinical Research: 73 (Cancer Treatment and Research, 73)
73% match

Anticancer Drug Resistance: Advances in Molecular and Clinical Research: 73 (Cancer Treatment and Research, 73)

Springer

£166.32 31 Aug 2026
Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done (Current Clinical Oncology)
73% match

Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done (Current Clinical Oncology)

Humana

£37.01 10 Aug 2026
Pancreatic Cancer: 177 (Recent Results in Cancer Research, 177)
73% match

Pancreatic Cancer: 177 (Recent Results in Cancer Research, 177)

Springer

£100.98 13 Aug 2026
Genitourinary Cancer 1: 6 (Cancer Treatment and Research, 6)
73% match

Genitourinary Cancer 1: 6 (Cancer Treatment and Research, 6)

Springer

£86.27 08 Aug 2026
DNA Methylation, Epigenetics and Metastasis: 7 (Cancer Metastasis - Biology and Treatment, 7)
73% match

DNA Methylation, Epigenetics and Metastasis: 7 (Cancer Metastasis - Biology and Treatment, 7)

Springer

£149.64 17 Oct 2026
Cancer Stem Cells: Emerging Concepts and Future Perspectives in Translational Oncology
73% match

Cancer Stem Cells: Emerging Concepts and Future Perspectives in Translational Oncology

Springer

£109.11 14 Sep 2026
Cancer Stem Cells: Methods and Protocols: 568 (Methods in Molecular Biology, 568)
72% match

Cancer Stem Cells: Methods and Protocols: 568 (Methods in Molecular Biology, 568)

Humana

£76.42 30 Aug 2026
Lung Cancer Metastasis: Novel Biological Mechanisms and Impact on Clinical Practice
72% match

Lung Cancer Metastasis: Novel Biological Mechanisms and Impact on Clinical Practice

Springer

£80.67 05 Aug 2026
Resistance to Targeted Therapies in Breast Cancer: 16 (Resistance to Targeted Anti-Cancer Therapeutics, 16)
72% match

Resistance to Targeted Therapies in Breast Cancer: 16 (Resistance to Targeted Anti-Cancer Therapeutics, 16)

Springer

£80.65 06 Aug 2026
Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances: 42 (Cancer Treatment and Research, 42)
72% match

Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances: 42 (Cancer Treatment and Research, 42)

Springer

£107.85 06 Aug 2026